New genetic marker linked to improved survival with immunotherapy in ovarian and other cancers

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without these mutations, according to researchers from The University of Texas MD Anderson Cancer Center.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup